Women in the United States have a 12.3% estimated lifetime risk for developing breast
cancer (ie, 1 in 8 women). 1 In 2009, an estimated 194,290 cases of invasive breast cancer (…

Talimogene laherparepvec (T-VEC) is an oncolytic virus hypothesized to enhance triple-negative
breast cancer (TNBC) responses to neoadjuvant chemotherapy (NAC). This article …

The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment
recommendations for common physical and psychosocial consequences of cancer and cancer …

The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment
recommendations for consequences of adult-onset cancer and its treatment, with the goal of …

Many cancer survivors experience menopausal symptoms, including female survivors
taking aromatase inhibitors or with a history of oophorectomy or chemotherapy, and male …

The NCCN Guidelines for Survivorship are intended to help healthcare professionals
working with cancer survivors to ensure that each survivor’s complex and varied needs are …

Background Triple negative breast cancer (TNBC) is an aggressive disease, but recent
studies have identified heterogeneity in patient outcomes. However, the utility of histologic …

The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment
recommendations for consequences of cancer and cancer treatment to aid healthcare professionals …

BACKGROUND. Patients with invasive cancer identified at the time of prophylactic mastectomy
(PM) will require axillary lymph node dissection for staging; therefore, many surgeons …

Purpose: Talimogene laherparepvec (TVEC) is an oncolytic herpes simplex 1 virus approved
for treatment of melanoma. We hypothesized intratumoral TVEC may enhance response to …